References
Louis DN, Holland EC, Cairncross JG, 2001 Glioma classification, a molecular reappraisal Am J Pathol 159: 779–786
Phuphanich S, Brat DJ, Olson JJ, 2004 Delivery systems and molecular targets of mechanism-based therapies for GBM Expert Rev Neurother 4: 649–663
Groves MD, Puduvalli VK, Hess KR, et al, 2002 Phase II trial of temozolomide plus the matrix metalloprotease inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme J Clin Oncol 20: 1383–1388
Levin V, Phuphanich S, Glantz MJ, et al, 2002 Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloprotease (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy Proceed ASCO 21: 26a
Fine HA, Figg WD, Jaeckle K, et al, 2000 Phase II trial of the antiangiogenic agent thalidomide in patients with recurrence high-grade gliomas J Clin Oncol 18: 708–715
Marx GM, Pavlakis N, McCowatt S, et al, 2001 Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme J Neurooncol 54: 31–38
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wong, E.T. Tumor growth, invasion, and angiogenesis in malignant gliomas. J Neurooncol 77, 295–296 (2006). https://doi.org/10.1007/s11060-005-9042-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-005-9042-8